Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744254 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL452290 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL12744248 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL15024820 | 0.98 | SIGMAR1 (0.46) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL15024795 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL2944852 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL4977548 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL12744255 | 0.95 | SIGMAR1 (0.46) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL13780595 | 0.95 | SIGMAR1 (0.46) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A | |
| SCHEMBL12744244 | 0.95 | SIGMAR1 (0.46) | SIGMAR1CYP2A6ALDH1A1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058552-A1 | Novel Aromatic Tertiary Amines and Use Thereof as Organic Electronic Functional Material | BANDO CHEMICAL INDUSTRIES, LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1829855-A1 | NOVEL AROMATIC TERTIARY AMINES AND UTILIZATION THEREOF AS ORGANIC ELECTRONIC FUNCTIONAL MATERIAL | BANDO CHEMICAL INDUSTRIES, LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058552-A1 | Novel Aromatic Tertiary Amines and Use Thereof as Organic Electronic Functional Material | SLC18A1, PAH, TYR | SIGMAR1 197/4885CYP2A6 388/4885ALDH1A1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.